The Evolving IP Landscape for Cancer Genomics Technology

By June 21, 2016Press Releases

TOMA Biosciences is establishing a strong intellectual property position through a broad and robust patent portfolio — including approved and pending patent applications in the U.S. and worldwide for TOMA’s proprietary oligonucleotide selective sequencing, library preparation assays, and related methods and technologies.

Soon TOMA’s intellectual property portfolio is expected to include a new European patent titled, “Methods for Stratifying and Annotating Cancer Drug Treatment Options,” that stakes claim to methods for identifying and disseminating targeted cancer drug treatment options to health care provides, based on an existing U.S. patent.

Cancer genomics technology is rapidly advancing worldwide, which is creating a complex and evolving intellectual property landscape. Learn more about these critical issues by attending our 30-minute webinar with Vern Norviel, Intellectual property attorney at Wilson Sonsini Goodrich & Rosati.